OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12-Week Clinical Trial

IF 2.3 4区医学 Q2 DERMATOLOGY

Journal of Cosmetic Dermatology Pub Date : 2025-04-07 DOI:10.1111/jocd.70169

Alessandra Zonari, Lear E. Brace, Luiza Brunelli Buhrer, Nathaniel H. O. Harder, Claire Harker, Adam B. Aronson, Caitlyn N. Tse, Carolina R. Oliveira, Mariana Boroni, Juliana L. Carvalho

{"title":"OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12-Week Clinical Trial","authors":"Alessandra Zonari, Lear E. Brace, Luiza Brunelli Buhrer, Nathaniel H. O. Harder, Claire Harker, Adam B. Aronson, Caitlyn N. Tse, Carolina R. Oliveira, Mariana Boroni, Juliana L. Carvalho","doi":"10.1111/jocd.70169","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>As the body's largest organ, the skin plays a crucial role in defending against external stressors. Skin characteristics change with age, decreasing skin barrier integrity and compromising skin and body health. This study aimed to investigate the potential of a topical formulation containing OS-01 (a.k.a. Peptide 14), a senotherapeutic peptide, to counteract age-related skin changes and their systemic consequences.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A randomized, double-blinded clinical trial involving 60 female volunteers aged 60–90 was conducted over 12 weeks. Participants received either an OS-01 topical formulation or a commercially available moisturizer control formulation. Skin parameters, subjective perceptions, and circulating cytokine levels were assessed. Skin instrumental analysis included transepidermal water loss (TEWL), skin hydration, and pH measurements.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Participants treated with the OS-01 topical formulation displayed significantly improved skin barrier function and hydration compared to the control group. Participant perceptions aligned with objective findings: after 12 weeks, 70% of participants in the OS-01 group noticed an improvement in general skin appearance versus 42% for the control group. The systemic levels of proinflammatory cytokines tended to normalize, with a significant decrease in IL-8 in the blood analysis of participants from the OS-01 group. On the other hand, the control group demonstrated an increase in a few circulating cytokines, particularly TNF-ɑ and IFN-γ. Moreover, GlycanAge analysis measuring participants' biological age suggested the slowing of systemic aging in the group treated with the OS-01 topical formulation.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The study suggests that the OS-01 formulation can impact skin health by improving the skin barrier function, potentially influencing systemic inflammation and biological age. In conclusion, the study supports that targeting skin health may contribute to better longevity outcomes, underscoring the skin's pivotal role in systemic aging and supporting an integrated approach to health management.</p>\n </section>\n </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"24 4","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.70169","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70169","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

As the body's largest organ, the skin plays a crucial role in defending against external stressors. Skin characteristics change with age, decreasing skin barrier integrity and compromising skin and body health. This study aimed to investigate the potential of a topical formulation containing OS-01 (a.k.a. Peptide 14), a senotherapeutic peptide, to counteract age-related skin changes and their systemic consequences.

Methods

A randomized, double-blinded clinical trial involving 60 female volunteers aged 60–90 was conducted over 12 weeks. Participants received either an OS-01 topical formulation or a commercially available moisturizer control formulation. Skin parameters, subjective perceptions, and circulating cytokine levels were assessed. Skin instrumental analysis included transepidermal water loss (TEWL), skin hydration, and pH measurements.

Results

Participants treated with the OS-01 topical formulation displayed significantly improved skin barrier function and hydration compared to the control group. Participant perceptions aligned with objective findings: after 12 weeks, 70% of participants in the OS-01 group noticed an improvement in general skin appearance versus 42% for the control group. The systemic levels of proinflammatory cytokines tended to normalize, with a significant decrease in IL-8 in the blood analysis of participants from the OS-01 group. On the other hand, the control group demonstrated an increase in a few circulating cytokines, particularly TNF-ɑ and IFN-γ. Moreover, GlycanAge analysis measuring participants' biological age suggested the slowing of systemic aging in the group treated with the OS-01 topical formulation.

Conclusion

The study suggests that the OS-01 formulation can impact skin health by improving the skin barrier function, potentially influencing systemic inflammation and biological age. In conclusion, the study supports that targeting skin health may contribute to better longevity outcomes, underscoring the skin's pivotal role in systemic aging and supporting an integrated approach to health management.

Abstract Image

查看原文本刊更多论文

OS-01肽局部配方改善皮肤屏障功能，减少全身炎症标志物：一项为期12周的试点临床试验

作为人体最大的器官，皮肤在抵御外界压力方面起着至关重要的作用。皮肤特征随着年龄的增长而变化，降低皮肤屏障的完整性，损害皮肤和身体健康。本研究旨在研究含有OS-01（又名肽14）的局部配方的潜力，这是一种老年治疗肽，可以抵消与年龄相关的皮肤变化及其全身后果。方法采用随机、双盲的临床试验方法，对60名60 ~ 90岁的女性志愿者进行为期12周的研究。参与者接受了OS-01局部配方或市售的润肤霜对照配方。评估皮肤参数、主观感觉和循环细胞因子水平。皮肤仪器分析包括经皮失水（TEWL）、皮肤水合作用和pH值测量。结果与对照组相比，接受OS-01外用制剂治疗的参与者皮肤屏障功能和水合作用明显改善。参与者的看法与客观结果一致：12周后，OS-01组70%的参与者注意到整体皮肤外观有所改善，而对照组的这一比例为42%。全身促炎细胞因子水平趋于正常化，OS-01组参与者血液分析中IL-8显著降低。另一方面，对照组表现出一些循环细胞因子的增加，特别是TNF-和IFN-γ。此外，测量参与者生物年龄的GlycanAge分析表明，使用OS-01外用制剂治疗组的全身衰老减慢。结论本研究提示OS-01配方可通过改善皮肤屏障功能影响皮肤健康，可能影响全身炎症和生物年龄。总之，该研究支持针对皮肤健康可能有助于更好的长寿结果，强调皮肤在系统性衰老中的关键作用，并支持综合健康管理方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cosmetic Dermatology DERMATOLOGY-

CiteScore

4.30

自引率

13.00%

发文量

818

审稿时长

>12 weeks

期刊介绍： The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques. The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.